A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation
Sponsor: BerGenBio ASA
Terminated
Lack of efficacy
Other terminated trials from BerGenBio ASA
Other Carcinoma, Non-Small-Cell Lung trials with similar outcome
A PHASE1/PHASE2 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is terminated or withdrawn. The trial is conducted by BerGenBio ASA and has accumulated 9 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Feb 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BerGenBio ASA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Bialystok, Poland , Bologna, Italy , Budapest, Hungary , Chicago, United States , Dallas, United States , Durham, United States and 17 more locations